M&As this week: Dendreon Pharmaceuticals, Agile Pharma, Takeda Pharmaceutical Company


Valeant Pharmaceuticals International subsidiary Dendreon Pharmaceuticals will be acquired by Sanpower Group.

Valeant will receive a cash consideration of $819.9m for the deal, which will be used to repay a term loan under its senior secured credit facility.

The acquisition is expected to be completed in the first half of 2017.

Indian pharmaceutical company Aurobindo Pharma's subsidiary Agile Pharma has signed a binding agreement with Magnum Capital Partners to acquire Portuguese company Generis Farmaceutica.

Based in the UK, Magnum Capital Partners is a private equity firm.

The acquisition includes a cash purchase consideration of €135m ($142.78m) and is expected to be completed next month.

Aurobindo Pharma aims to expand its business in Portugal through the acquisition.

"Takeda Pharmaceutical Company will acquire Ariad Pharmaceuticals for $5.2bn, which will be funded through existing cash and up to $4bn of new debt."

Takeda Pharmaceutical Company will acquire Ariad Pharmaceuticals for $5.2bn, which will be funded through existing cash and up to $4bn of new debt.

The tender offer represents a purchase consideration of $24 a share, which is a 75% premium over the target company’s closing price on 6 January this year.

The transaction is expected to be completed by the end of next month, as well as enable Takeda Pharma to primarily expand its oncology portfolio.

Takeda Pharma is based in Japan, whereas Ariad Pharma is based in the US.

US-based OmicSoft Corporation has been acquired by Qiagen, a sample and assay technologies provider based in the Netherlands, with the aim of enhancing the latter’s bioinformatics portfolio.

The target company provides bioinformatics, next-generation sequencing, and cancer genomics solutions.